The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.s

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

Separating drug-induced from IBD-associated granulomatosis with polyangiitis can be extremely challenging (PMID 24525506)

Publications

Vaszar LT, Orzechowski NM, Specks U, Ytterberg SR, Loftus EV Jr, Mark EJ, Tazelaar HD

Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease.

The American journal of surgical pathology. 2014;38(3):354-9

Miura N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H

Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.

Clinical nephrology. 2009;71(1):74-9

Nanayakkara PW, de Jong E, Postmus PE

Bilateral pulmonary infiltrates in a patient with ulcerative colitis receiving mesalazine.

European journal of internal medicine. 2004;15(7):470-472

Choi HK, Merkel PA, Walker AM, Niles JL

Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.

Arthritis and rheumatism. 2000;43(2):405-13

Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA

Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis.

Chest. 1996;110(2):556-9